X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dishman Pharma with Strides Arcolab - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs STRIDES SHASUN LTD - Comparison Results

DISHMAN PHARMA    Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

STRIDES SHASUN LTD 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA STRIDES SHASUN LTD DISHMAN PHARMA/
STRIDES SHASUN LTD
 
P/E (TTM) x 25.1 13.2 190.7% View Chart
P/BV x 3.3 1.5 219.5% View Chart
Dividend Yield % 0.7 0.6 102.3%  

Financials

 DISHMAN PHARMA   STRIDES SHASUN LTD
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
STRIDES SHASUN LTD
Mar-17
DISHMAN PHARMA/
STRIDES SHASUN LTD
5-Yr Chart
Click to enlarge
High Rs3741,275 29.4%   
Low Rs129918 14.0%   
Sales per share (Unadj.) Rs197.8389.6 50.8%  
Earnings per share (Unadj.) Rs21.228.0 75.8%  
Cash flow per share (Unadj.) Rs34.748.9 71.0%  
Dividends per share (Unadj.) Rs2.004.50 44.4%  
Dividend yield (eoy) %0.80.4 193.6%  
Book value per share (Unadj.) Rs179.9303.1 59.3%  
Shares outstanding (eoy) m80.6989.42 90.2%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x1.32.8 45.2%   
Avg P/E ratio x11.939.2 30.3%  
P/CF ratio (eoy) x7.222.4 32.3%  
Price / Book Value ratio x1.43.6 38.7%  
Dividend payout %9.416.1 58.6%   
Avg Mkt Cap Rs m20,30698,036 20.7%   
No. of employees `0000.85.8 14.3%   
Total wages/salary Rs m5,3555,881 91.1%   
Avg. sales/employee Rs Th19,252.76,005.9 320.6%   
Avg. wages/employee Rs Th6,459.51,014.0 637.0%   
Avg. net profit/employee Rs Th2,064.1431.2 478.7%   
INCOME DATA
Net Sales Rs m15,96134,834 45.8%  
Other income Rs m2651,686 15.7%   
Total revenues Rs m16,22636,520 44.4%   
Gross profit Rs m4,1036,428 63.8%  
Depreciation Rs m1,0911,872 58.3%   
Interest Rs m9442,269 41.6%   
Profit before tax Rs m2,3343,973 58.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m14 30.6%   
Extraordinary Inc (Exp) Rs m0-1,006 0.0%   
Tax Rs m624470 132.7%   
Profit after tax Rs m1,7112,501 68.4%  
Gross profit margin %25.718.5 139.3%  
Effective tax rate %26.711.8 225.9%   
Net profit margin %10.77.2 149.3%  
BALANCE SHEET DATA
Current assets Rs m11,01838,165 28.9%   
Current liabilities Rs m9,51730,402 31.3%   
Net working cap to sales %9.422.3 42.2%  
Current ratio x1.21.3 92.2%  
Inventory Days Days11077 142.9%  
Debtors Days Days35104 33.3%  
Net fixed assets Rs m16,30437,639 43.3%   
Share capital Rs m161894 18.0%   
"Free" reserves Rs m12,90726,210 49.2%   
Net worth Rs m14,51627,105 53.6%   
Long term debt Rs m4,18916,377 25.6%   
Total assets Rs m29,80581,168 36.7%  
Interest coverage x3.52.8 126.2%   
Debt to equity ratio x0.30.6 47.8%  
Sales to assets ratio x0.50.4 124.8%   
Return on assets %8.95.9 151.6%  
Return on equity %11.89.2 127.8%  
Return on capital %17.512.1 145.5%  
Exports to sales %24.80-   
Imports to sales %3.70-   
Exports (fob) Rs m3,956NA-   
Imports (cif) Rs m596NA-   
Fx inflow Rs m4,95213,465 36.8%   
Fx outflow Rs m6974,076 17.1%   
Net fx Rs m4,2559,389 45.3%   
CASH FLOW
From Operations Rs m2,7862,881 96.7%  
From Investments Rs m-1,529-7,051 21.7%  
From Financial Activity Rs m-9413,382 -27.8%  
Net Cashflow Rs m316-788 -40.2%  

Share Holding

Indian Promoters % 61.4 27.7 221.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.7 37.8 9.8%  
FIIs % 12.7 8.6 147.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 25.9 85.3%  
Shareholders   46,261 56,241 82.3%  
Pledged promoter(s) holding % 35.8 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   BIOCON LTD  CADILA HEALTHCARE  SUVEN LIFE  DR. DATSONS LABS  GLENMARK PHARMA  

Compare DISHMAN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA 8-QTR ANALYSIS

COMPARE DISHMAN PHARMA WITH

MARKET STATS